Insights and Resources

Penetration Testing Reports, Guides, and Practical
Knowledge

Use these insights and resources to prepare for your next engagement, evaluate a vendor against real standards, or simply understand what attackers are doing right now.

Sample Deliverable

This is what a client receives at the close of an engagement, all three reports, identifying details removed. Structure, scoring, and remediation guidance are exactly as delivered.

Sample Report

The Complete Engagement Reports

Your board needs to understand exposure. Your security team needs to fix it. Your auditors need proof it happened. The Risk Impact Brief, the Technical Pentest Report, and the Attestation Letter deliver all three, from the same engagement.

Executive summary with risk posture overview
Critical and high severity vulnerabilities with CVSS scoring
Steps to reproduce, with proof-of-concept evidence
Remediation path for every vulnerability
Compliance control mapping throughout

PENETRATION TEST REPORT REDACTED

Critical 9.8

High 8.1

High 7.6

Blogs

Actionable Insights

A Medical Device Maker's Guide to FDA Cybersecurity Testing for 510(k) & PMA

The FDA doesn't publish a pen testing checklist, but its guidance, 524B requirements, and reviewer expectations add up to one. Here's what medical device makers must cover before, during, and after the test.

Pharma Pen Testing: Why FDA and IP Risk Need Different Scoping

Standard pen test scoping frameworks weren't built for pharma. Learn how to scope an engagement that covers validated systems under 21 CFR Part 11 and protects high-value formulation and clinical data from targeted threats.

FDA-524B-Medical-Device-Cybersecurity-Testing

FDA 524B Is Here: What Medical Device Makers Must Test Now

Section 524B made medical device cybersecurity a legal requirement, not a guideline. Learn what the FDA expects from your pen test scope, evidence package, and postmarket vulnerability management process.

Why CHIPS Act Manufacturers Can't Rely on CMMC Pen Testing Alone

Semiconductor manufacturers face dual compliance obligations under CMMC 2.0 and the CHIPS Act and a standard pen test satisfies neither fully. Learn how to build a unified program that covers both frameworks.

Why Pen Test Evidence Fails C3PAO Assessments (and How to Fix It)

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.

Threat Briefs

What Is Showing Up in Live Engagements

Each brief reflects a pattern our penetration testing team encountered more than once, across different clients, in the same testing window.

Medical Devices

FDA 524B Is Here: What Medical Device Makers Must Test Now

Guidance was advisory. 524B is law. The FDA can now refuse premarket submissions outright if the cybersecurity documentation falls short, and pen testing is part of what they're checking for.

Read brief

Pharma

Why Pharma Needs Penetration Testing for Nation-State Threats

The COVID vaccine IP theft campaigns weren't an anomaly. Nation-state actors have targeted pharma with the same persistence they bring to defense contractors, and standard security testing wasn't built for that threat model.

Read brief

R&D / GxP

Why R&D and Regulated Systems Need Different Penetration Testing Scopes

One environment is built for researcher speed. The other is built for data integrity and revalidation risk. Testing both with the same scope gets you results that serve neither.

Read brief

From the Practice

Explore More Insights From DivIHN

Explore perspectives on security testing, compliance, risk, and the challenges organizations face in today's threat landscape.

A Medical Device Maker's Guide to FDA Cybersecurity Testing for 510(k) & PMA

The FDA doesn't publish a pen testing checklist, but its guidance, 524B requirements, and reviewer expectations add up to one. Here's what medical device makers must cover before, during, and after the test.

Pharma Pen Testing: Why FDA and IP Risk Need Different Scoping

Standard pen test scoping frameworks weren't built for pharma. Learn how to scope an engagement that covers validated systems under 21 CFR Part 11 and protects high-value formulation and clinical data from targeted threats.

FDA 524B Is Here: What Medical Device Makers Must Test Now

Section 524B made medical device cybersecurity a legal requirement, not a guideline. Learn what the FDA expects from your pen test scope, evidence package, and postmarket vulnerability management process.

Why CHIPS Act Manufacturers Can't Rely on CMMC Pen Testing Alone

Semiconductor manufacturers face dual compliance obligations under CMMC 2.0 and the CHIPS Act and a standard pen test satisfies neither fully. Learn how to build a unified program that covers both frameworks.

Why Pen Test Evidence Fails C3PAO Assessments (and How to Fix It)

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.

Stay Sharp